11 research outputs found

    EPIDEMIOLOGY OF TRACK & FIELD INJURIES: A ONE YEAR EXPERIENCE IN ATHLETIC SCHOOLS

    Get PDF
    The purpose of this study was to record injuries in track & field events that were sustained by students who attended the athletic schools during a one-year period. From September 2009 to May 2010, the researchers observed 2045 students (883 males and 1163 females), who were participating in track and field events at the mentioned schools. During the study period 150 injuries were recorded, which accounted for 13.3% of all injuries sustained by students. Most of the injuries (34%) according to the diagnosis were sprains and strains and occurred during the months of February, December and January. A large percentage of the injuries (45.4%) were sustained by students who attended the Athletic Schools, which operated in the urban region. Students who attended the second class sustained more injuries than the other classes (first and third). Students who were practising or competing on a tartan playing surface were more likely to sustain an injury. Knee and ankle were the most frequent anatomical sites in which injuries (43.9%) occurred. Additionally, 80.0% of injuries occurred in students who were practising or competing in running events. No statistical differences were observed in all above mentioned parameters amongst male and female students. Physical education (P.E.) teachers should place more emphasis on prevention measures. These measures should include proper supervision of students during training, warming up and cooling down sessions with stretching techniques. By following these suggestions students will compete in a safe and healthy environment

    The effects of endurance training on selected coronary risk factors in children

    No full text
    The effects of regular aerobic exercise on blood concentrations on high-density lipoprotein cholesterol and prostacyclin were studied in 18 healthy sedentary boys who exercised on a bicycle ergometer for 1 h, four times per week, for 2 months at 75% of their physical working capacity. The results were compared with those of 10 control boys who did not participate in any specific program. The exercise group revealed a significantly higher mean high-density lipoprotein cholesterol and 6-keto-PGF1a concentration at the end of the training program (p < 0.005 and p < 0.001, respectively). These results suggest that regular aerobic exercise has beneficial effects upon the high-density lipoprotein cholesterol and 6-keto-PGF1a in healthy young boys and may be beneficial in the long term, by preventing atherosclerosis of coronary artery disease in adulthood

    MAP4K4 controlled integrin β1 activation and c-Met endocytosis are associated with invasive behavior of medulloblastoma cells

    Get PDF
    Local tissue infiltration of Medulloblastoma (MB) tumor cells precedes metastatic disease but little is still known about intrinsic regulation of migration and invasion in these cells. We found that MAP4K4, a pro-migratory Ser/Thr kinase, is overexpressed in 30% of primary MB tumors and that increased expression is particularly associated with the frequently metastatic SHH β subtype. MAP4K4 is a driver of migration and invasion downstream of c-Met, which is transcriptionally up-regulated in SHH MB. Consistently, depletion of MAP4K4 in MB tumor cells restricts HGF-driven matrix invasion in vitro and brain tissue infiltration ex vivo. We show that these pro-migratory functions of MAP4K4 involve the activation of the integrin β-1 adhesion receptor and are associated with increased endocytic uptake. The consequent enhanced recycling of c-Met caused by MAP4K4 results in the accumulation of activated c-Met in cytosolic vesicles, which is required for sustained signaling and downstream pathway activation. The parallel increase of c-Met and MAP4K4 expression in SHH MB could predict an increased potential of these tumors to infiltrate brain tissue and cause metastatic disease. Molecular targeting of the underlying accelerated endocytosis and receptor recycling could represent a novel approach to block pro-migratory effector functions of MAP4K4 in metastatic cancers

    TGF-β Determines the Pro-migratory Potential of bFGF Signaling in Medulloblastoma

    Get PDF
    The microenvironment shapes cell behavior and determines metastatic outcomes of tumors. We addressed how microenvironmental cues control tumor cell invasion in pediatric medulloblastoma (MB). We show that bFGF promotes MB tumor cell invasion through FGF receptor (FGFR) in vitro and that blockade of FGFR represses brain tissue infiltration in vivo. TGF-β regulates pro-migratory bFGF function in a context-dependent manner. Under low bFGF, the non-canonical TGF-β pathway causes ROCK activation and cortical translocation of ERK1/2, which antagonizes FGFR signaling by inactivating FGFR substrate 2 (FRS2), and promotes a contractile, non-motile phenotype. Under high bFGF, negative-feedback regulation of FRS2 by bFGF-induced ERK1/2 causes repression of the FGFR pathway. Under these conditions, TGF-β counters inactivation of FRS2 and restores pro-migratory signaling. These findings pinpoint coincidence detection of bFGF and TGF-β signaling by FRS2 as a mechanism that controls tumor cell invasion. Thus, targeting FRS2 represents an emerging strategy to abrogate aberrant FGFR signaling

    Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals

    Get PDF
    OBJECTIVES: To explore contemporary antibiotic management of infections caused by carbapenem-resistant Gram-negative bacteria in hospitals. METHODS: Cross-sectional, internet-based questionnaire survey. We contacted representatives of all hospitals with more than 800 acute-care hospital beds in France, Greece, Israel, Italy, Kosovo, Slovenia, Spain and selected hospitals in the USA. We asked respondents to describe the most common actual practice at their hospital regarding management of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa through close-ended questions. RESULTS: Between January and June 2017, 115 of 141 eligible hospitals participated (overall response rate 81.6%, country-specific rates 66.7%-100%). Most were tertiary-care (99/114, 86.8%), university-affiliated (110/115, 89.1%) hospitals and most representatives were infectious disease specialists (99/115, 86.1%). Combination therapy was prescribed in 114/115 (99.1%) hospitals at least occasionally. Respondents were more likely to consider combination therapy when treating bacteraemia, pneumonia and central nervous system infections and for Enterobacteriaceae, P. aeruginosa and A. baumannii similarly. Combination of a polymyxin with a carbapenem was used in most cases, whereas combinations of a polymyxin with tigecycline, an aminoglycoside, fosfomycin or rifampicin were also common. Monotherapy was used for treatment of complicated urinary tract infections, usually with an aminoglycoside or a polymyxin. The intended goal of combination therapy was to improve the effectiveness of the treatment and to prevent development of resistance. In general, respondents shared the misconception that combination therapy is supported by strong scientific evidence. CONCLUSIONS: Combination therapy was the preferred treatment strategy for infections caused by carbapenem-resistant Gram-negative bacteria among hospital representatives, even though high-quality evidence for carbapenem-based combination therapy is lacking

    Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals

    No full text
    Objectives: To explore contemporary antibiotic management of infections caused by carbapenem-resistant Gram-negative bacteria in hospitals. Methods: Cross-sectional, internet-based questionnaire survey. We contacted representatives of all hospitals with more than 800 acute-care hospital beds in France, Greece, Israel, Italy, Kosovo, Slovenia, Spain and selected hospitals in the USA. We asked respondents to describe the most common actual practice at their hospital regarding management of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa through close-ended questions. Results: Between January and June 2017, 115 of 141 eligible hospitals participated (overall response rate 81.6%, country-specific rates 66.7%–100%). Most were tertiary-care (99/114, 86.8%), university-affiliated (110/115, 89.1%) hospitals and most representatives were infectious disease specialists (99/115, 86.1%). Combination therapy was prescribed in 114/115 (99.1%) hospitals at least occasionally. Respondents were more likely to consider combination therapy when treating bacteraemia, pneumonia and central nervous system infections and for Enterobacteriaceae, P. aeruginosa and A. baumannii similarly. Combination of a polymyxin with a carbapenem was used in most cases, whereas combinations of a polymyxin with tigecycline, an aminoglycoside, fosfomycin or rifampicin were also common. Monotherapy was used for treatment of complicated urinary tract infections, usually with an aminoglycoside or a polymyxin. The intended goal of combination therapy was to improve the effectiveness of the treatment and to prevent development of resistance. In general, respondents shared the misconception that combination therapy is supported by strong scientific evidence. Conclusions: Combination therapy was the preferred treatment strategy for infections caused by carbapenem-resistant Gram-negative bacteria among hospital representatives, even though high-quality evidence for carbapenem-based combination therapy is lacking. © 2018 European Society of Clinical Microbiology and Infectious Disease

    Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals

    Get PDF
    107noneObjectives: To explore contemporary antibiotic management of infections caused by carbapenem-resistant Gram-negative bacteria in hospitals.Methods: Cross-sectional, internet-based questionnaire survey. We contacted representatives of all hospitals with more than 800 acute-care hospital beds in France, Greece, Israel, Italy, Kosovo, Slovenia, Spain and selected hospitals in the USA. We asked respondents to describe the most common actual practice at their hospital regarding management of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa through close-ended questions.Results: Between January and June 2017, 115 of 141 eligible hospitals participated (overall response rate 81.6%, country-specific rates 66.7%-100%). Most were tertiary-care (99/114, 86.8%), university-affiliated (110/115, 89.1%) hospitals and most representatives were infectious disease specialists (99/115, 86.1%). Combination therapy was prescribed in 114/115 (99.1%) hospitals at least occasionally. Respondents were more likely to consider combination therapy when treating bacteraemia, pneumonia and central nervous system infections and for Enterobacteriaceae, P. aeruginosa and A. baumannii similarly. Combination of a polymyxin with a carbapenem was used in most cases, whereas combinations of a polymyxin with tigecycline, an aminoglycoside, fosfomycin or rifampicin were also common. Monotherapy was used for treatment of complicated urinary tract infections, usually with an aminoglycoside or a polymyxin. The intended goal of combination therapy was to improve the effectiveness of the treatment and to prevent development of resistance. In general, respondents shared the misconception that combination therapy is supported by strong scientific evidence.Conclusions: Combination therapy was the preferred treatment strategy for infections caused by carbapenem-resistant Gram-negative bacteria among hospital representatives, even though high-quality evidence for carbapenem-based combination therapy is lacking. (c) 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.nonePapst, L.*; Beović, B.; Pulcini, C.; Durante-Mangoni, E.; Rodríguez-Baño, J.; Kaye, K.S.; Daikos, G.L.; Raka, L.; Paul, M.; Abbo, L.; Abgueguen, P.; Almirante, B.; Azzini, A.M.; Bani-Sadr, F.; Bassetti, M.; Ben-Ami, R.; Beović, B.; Béraud, G.; Botelho-Nevers, E.; Bou, G.; Boutoille, D.; Cabié, A.; Cacopardo, B.; Cascio, A.; Cassir, N.; Castelli, F.; Cecala, M.; Charmillon, A.; Chirouze, C.; Cisneros, J.M.; Colmenero, J.D.; Coppola, N.; Corcione, S.; Daikos, G.L.; Dalla Gasperina, D.; De la Calle Cabrera, C.; Delobel, P.; Di Caprio, D.; Durante Mangoni, E.; Dupon, M.; Ettahar, N.; Falagas, M.E.; Falcone, M.; Fariñas, M.C.; Faure, E.; Forestier, E.; Foti, G.; Gallagher, J.; Gattuso, G.; Gendrin, V.; Gentile, I.; Giacobbe, D.R.; Gogos, C.A.; Grandiere Perez, L.; Hansmann, Y.; Horcajada, J.P.; Iacobello, C.; Jacob, J.T.; Justo, J.A.; Kernéis, S.; Komnos, A.; Kotnik Kevorkijan, B.; Lebeaux, D.; Le Berre, R.; Lechiche, C.; Le Moxing, V.; Lescure, F.X.; Libanore, M.; Martinot, M.; Merino de Lucas, E.; Mondain, V.; Mondello, P.; Montejo, M.; Mootien, J.; Muñoz, P.; Nir-Paz, R.; Pan, A.; Paño-Pardo, J.R.; Patel, G.; Paul, M.; Pérez Rodríguez, M.T.; Piroth, L.; Pogue, J.; Potoski, B.A.; Pourcher, V.; Pyrpasopoulou, A.; Rahav, G.; Rizzi, M.; Rodríguez-Baño, J.; Salavert, M.; Scheetz, M.; Sims, M.; Spahija, G.; Stefani, S.; Stefos, A.; Tamma, P.D.; Tattevin, P.; Tedesco, A.; Torre-Cisneros, J.; Tripolitsioti, P.; Tsiodras, S.; Uomo, G.; Verdon, R.; Viale, P.; Vitrat, V.; Weinberger, M.; Wiener-Well, Y.Papst, L.; Beović, B.; Pulcini, C.; Durante-Mangoni, E.; Rodríguez-Baño, J.; Kaye, K. S.; Daikos, G. L.; Raka, L.; Paul, M.; Abbo, L.; Abgueguen, P.; Almirante, B.; Azzini, A. M.; Bani-Sadr, F.; Bassetti, M.; Ben-Ami, R.; Beović, B.; Béraud, G.; Botelho-Nevers, E.; Bou, G.; Boutoille, D.; Cabié, A.; Cacopardo, B.; Cascio, A.; Cassir, N.; Castelli, F.; Cecala, M.; Charmillon, A.; Chirouze, C.; Cisneros, J. M.; Colmenero, J. D.; Coppola, N.; Corcione, S.; Daikos, G. L.; Dalla Gasperina, D.; De la Calle Cabrera, C.; Delobel, P.; Di Caprio, D.; Durante Mangoni, E.; Dupon, M.; Ettahar, N.; Falagas, M. E.; Falcone, M.; Fariñas, M. C.; Faure, E.; Forestier, E.; Foti, G.; Gallagher, J.; Gattuso, G.; Gendrin, V.; Gentile, I.; Giacobbe, D. R.; Gogos, C. A.; Grandiere Perez, L.; Hansmann, Y.; Horcajada, J. P.; Iacobello, C.; Jacob, J. T.; Justo, J. A.; Kernéis, S.; Komnos, A.; Kotnik Kevorkijan, B.; Lebeaux, D.; Le Berre, R.; Lechiche, C.; Le Moxing, V.; Lescure, F. X.; Libanore, M.; Martinot, M.; Merino de Lucas, E.; Mondain, V.; Mondello, P.; Montejo, M.; Mootien, J.; Muñoz, P.; Nir-Paz, R.; Pan, A.; Paño-Pardo, J. R.; Patel, G.; Paul, M.; Pérez Rodríguez, M. T.; Piroth, L.; Pogue, J.; Potoski, B. A.; Pourcher, V.; Pyrpasopoulou, A.; Rahav, G.; Rizzi, M.; Rodríguez-Baño, J.; Salavert, M.; Scheetz, M.; Sims, M.; Spahija, G.; Stefani, S.; Stefos, A.; Tamma, P. D.; Tattevin, P.; Tedesco, A.; Torre-Cisneros, J.; Tripolitsioti, P.; Tsiodras, S.; Uomo, G.; Verdon, R.; Viale, P.; Vitrat, V.; Weinberger, M.; Wiener-Well, Y

    Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals

    No full text
    corecore